Jason Ian Simon

Address:

2282 Misty Rdg Dr, Lenoir City, TN 37772

Phone:

8659884815

VIN:

1D8HB58297F502336

Make:

DODGE

Model:

DURANGO

Year:

2007

Address:

7675 Phoenix Dr APT 429, Houston, TX 77030

Phone:

2814125801

VIN:

1G1YY26U775117503

Make:

CHEVROLET

Model:

CORVETTE

Year:

2007

US Patent:

7338772, Mar 4, 2008

Filed:

Apr 10, 2003

Appl. No.:

10/411545

Inventors:

Ying Jiang - Scotch Plains NJ, US
Fang Liang Zhang - Fanwood NJ, US
Nicholas J. Murgolo - Millington NJ, US
Lin Luo - Edison NJ, US
Jason S. Simon - Westfield NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

G01N 33/566

US Classification:

435 721, 435 72, 436501

Abstract:

The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.

US Patent:

7807390, Oct 5, 2010

Filed:

Jan 7, 2008

Appl. No.:

11/970276

Inventors:

Ying Jiang - Scotch Plains NJ, US
Fang Liang Zhang - Fanwood NJ, US
Nicholas J. Murgolo - Millington NJ, US
Lin Luo - Edison NJ, US
Jason S. Simon - Westfield NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

G01N 33/566
C07K 14/705

US Classification:

435 721, 435 71, 435 72, 436501

Abstract:

The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.

US Patent:

8133980, Mar 13, 2012

Filed:

Oct 1, 2010

Appl. No.:

12/896297

Inventors:

Ying Jiang - Scotch Plains NJ, US
Fang Liang Zhang - Fanwood NJ, US
Nicholas J. Murgolo - Millington NJ, US
Lin Luo - Edison NJ, US
Jason S. Simon - Westfield NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07K 16/00
C12P 21/08

US Classification:

5303879, 5303881, 53038815, 4241391

Abstract:

The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.

US Patent:

8535887, Sep 17, 2013

Filed:

May 21, 2010

Appl. No.:

12/785060

Inventors:

Arthur Bertelsen - Ridgewood NJ, US
Jacques Fellay - Durham NC, US
Dongliang Ge - Raleigh NC, US
David B. Goldstein - Durham NC, US
John G. McHutchison - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Jason S. Simon - Westfield NJ, US
Alexander J. Thompson - Durham NJ, US
Thomas Urban - Durham NC, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C12Q 1/70
C12Q 1/68

US Classification:

435 611, 435 5, 435 61, 435 612

Abstract:

The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients.

US Patent:

20090192135, Jul 30, 2009

Filed:

Mar 28, 2006

Appl. No.:

11/887346

Inventors:

Jason Samuel Simon - Westfield NJ, US
Maha Chabhar Karnoub - Doylestown PA, US
Michael E. Severino - Westlake Village CA, US
David James Devlin - New City NY, US
Andrew Stewart Plump - Westfield NJ, US
Eric E. Schadt - Kirkland WA, US

Assignee:

SCHERING CORPORATION - Kenilworth NJ
MERCK & CO., INC. - Rahway NJ
ROSETTA INPHARMATICS LLC - Seattle WA

International Classification:

A61K 31/397
C12Q 1/60
C12Q 1/68
C40B 30/04
C07H 21/04

US Classification:

51421002, 435 11, 435 6, 506 9, 536 235

Abstract:

The present invention relates to the identification and use of single nucleotide polymorphisms and haplotypes in the Niemann Pick C1-Like 1 (NPC1L1) gene. In particular, methods are provided for correlating NPC1L1 polymorphisms and haplo-types with the responsiveness of a pharmaceutically active compound administered to a human subject. The invention further relates to a method for estimating the responsiveness of a pharmaceutically active compound administered to a human subject which method comprises determining at least one polymorphism in the NPC1L1 gene. The methods are based on determining polymorphisms in the NPC1L1 gene and correlating the responsiveness of a pharmaceutically active compound in the human by reference to one or more polymorphism in NPC1L1. The invention further relates to isolated nucleic acids comprising within their sequence the polymorphisms as defined herein, to nucleic acid primers and oligonucleotide probes capable of hybridizing to such nucleic acids and to a diagnostic kit comprising one or more of such primers and probes for detecting a polymorphism in the NPC1L1 gene.

US Patent:

20110158944, Jun 30, 2011

Filed:

Nov 26, 2008

Appl. No.:

12/745031

Inventors:

Thomas J. Hosted - Summit NJ, US
Jason S. Simon - Westfield NJ, US
Marc M. Delorenzo - East Hanover NJ, US
Donna Marie Carr - Kenilworth NJ, US
William T. Windsor - East Brunswick NJ, US
Ahmed A. Samatar - West Windsor NJ, US

International Classification:

A61K 38/21
C12Q 1/68
A61P 35/00

US Classification:

424 857, 435 612

Abstract:

The present invention provides, inter alia, methods for predicting the sensitivity of a disease, such as cancer, to an ERK1 or ERK2 or MEK inhibitor by detecting the presence of an allele of BRAF in cells mediating the disease. Methods of treatment are also provided.

US Patent:

20180209980, Jul 26, 2018

Filed:

Mar 23, 2018

Appl. No.:

15/934242

Inventors:

- Tokyo, JP
Tadashi Kadowaki - Tsukuba, JP
Junji Matsui - Tsukuba, JP
Jason S. Simon - Woodcliff Lake NJ, US
Lucy Xu - Woodcliff Lake NJ, US

Assignee:

Eisai R&D Management Co., Ltd. - Tokyo

International Classification:

G01N 33/574
C12Q 1/6886
A61K 31/47

Abstract:

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

US Patent:

20140187577, Jul 3, 2014

Filed:

May 31, 2012

Appl. No.:

14/122339

Inventors:

Yasuhiro Funahashi - Tsukuba-shi, JP
Tadashi Kadowaki - Tsukuba-shi, JP
Junji Matsui - Tsukuba-shi, JP
Jason S. Simon - Woodcliff Lake NJ, US
Lucy Xu - Woodcliff Lake NJ, US

Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo

International Classification:

G01N 33/574
A61K 31/47
C12Q 1/68

US Classification:

514312, 435 611, 435 792

Abstract:

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.